risedronic acid has been researched along with Disease Models, Animal in 45 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this study, we investigated the potential of thiolated chitosan-based mucoadhesive film, loaded with risedronate sodium in the treatment of osteoporosis." | 7.88 | Improvement of bone microarchitecture in methylprednisolone induced rat model of osteoporosis by using thiolated chitosan-based risedronate mucoadhesive film. ( Anbu, J; Azamthulla, M; Banala, VT; Mukherjee, D; Ramachandra, SG; Srinivasan, B, 2018) |
| "In this study, we investigated the potential of thiolated chitosan-based mucoadhesive film, loaded with risedronate sodium in the treatment of osteoporosis." | 3.88 | Improvement of bone microarchitecture in methylprednisolone induced rat model of osteoporosis by using thiolated chitosan-based risedronate mucoadhesive film. ( Anbu, J; Azamthulla, M; Banala, VT; Mukherjee, D; Ramachandra, SG; Srinivasan, B, 2018) |
| " Biochemical and in-vivo pharmacokinetic studies on osteoporotic rat model treated with different formulations were performed." | 1.43 | Revisiting bone targeting potential of novel hydroxyapatite based surface modified PLGA nanoparticles of risedronate: Pharmacokinetic and biochemical assessment. ( Ahmad, FJ; Ahmad, I; Gupta, S; Pandey, S; Rawat, P; Talegaonkar, S; Thomas, SC; Vohora, D, 2016) |
| "Osteoarthritis is thought to be the most prevalent chronic and disabling joint disease in animals and humans and its treatment is a major orthopaedic challenge because there is no ideal drug treatment to preserve joint structure and function, as well as to ameliorate the symptomatology of the disease." | 1.42 | Comparison of various SYSADOA for the osteoarthritis treatment: an experimental study in rabbits. ( Caeiro, JR; González-Cantalapiedra, A; Guede, D; López-Peña, M; Muñoz, F; Permuy, M, 2015) |
| "Alendronate treatment reduced bony osteophyte development." | 1.36 | In vivo microfocal computed tomography and micro-magnetic resonance imaging evaluation of antiresorptive and antiinflammatory drugs as preventive treatments of osteoarthritis in the rat. ( Doschak, MR; Jones, MD; Li, G; Maksymowych, WP; Tran, CW; Zernicke, RF, 2010) |
| "Otosclerosis is a bony dyscrasia characterized by histopathological findings of osteoclast production." | 1.35 | Medical treatment of otosclerosis: rationale for use of bisphosphonates. ( Brookler, K, 2008) |
| " In two groups, anterior cruciate ligament transection was performed and half were left untreated, and the other half dosed with risedronate (0." | 1.35 | Preservation of periarticular cancellous morphology and mechanical stiffness in post-traumatic experimental osteoarthritis by antiresorptive therapy. ( Boyd, SK; Doschak, MR; MacNeil, JA; Zernicke, RF, 2008) |
| "Osteoporosis is a severe complication of glucocorticoid treatment." | 1.34 | Risedronate prevents the loss of microarchitecture in glucocorticoid-induced osteoporosis in rats. ( Bertoldo, F; Dalle Carbonare, L; Fassina, A; Giannini, S; Lo Cascio, V; Realdi, G; Sella, S; Turco, G; Valenti, MT; Zordan, S, 2007) |
| "The purposes of the present study were to differentiate the effects of pre-surgery treatment with risedronate and post-surgery treatment with a reduced dosing frequency of risedronate on trabecular bone loss in ovariectomized rats and to determine whether post-surgery treatment with a reduced dosing frequency of risedronate would have a beneficial effect on trabecular bone loss after pre-surgery treatment with risedronate by means of bone histomorphometric analysis." | 1.33 | Effect of pre- and post-surgery treatment with risedronate on trabecular bone loss in ovariectomized rats. ( Iwamoto, J; Sato, Y; Shen, CL; Takeda, T; Yeh, JK, 2006) |
| "The purpose of the present study was to examine the effect of pretreatment with risedronate and/or vitamin K2 and treatment continuation with reduced dosing frequency of the drugs on the early cancellous bone loss induced by ovariectomy (OVX) in rats." | 1.33 | Beneficial effect of pretreatment and treatment continuation with risedronate and vitamin K2 on cancellous bone loss after ovariectomy in rats: a bone histomorphometry study. ( Iwamoto, J; Sato, Y; Shen, CL; Takeda, T; Yeh, JK, 2006) |
| "A murine model of acute Chagas' disease was used, in which experimental animals were infected with 10(3) trypomastigotes and intravenous treatment was started 24 h post-infection." | 1.32 | Antiparasitic activity of risedronate in a murine model of acute Chagas' disease. ( Baptista, MM; Britto, CC; de Castro, SL; Docampo, R; Garzoni, LR; Meirelles, Mde N; Oldfield, E; Urbina, JA; Waghabi, MC, 2004) |
| " The purpose was to determine the effects of the anti-resorptive agents alone and in combination with intermittent PTH on bone formation in the mandible and a long bone in the aged ovariectomized (Ovx) rat." | 1.31 | Mandibular bone formation rates in aged ovariectomized rats treated with anti-resorptive agents alone and in combination with intermittent parathyroid hormone. ( Hunziker, J; Miller, SC; Wronski, TJ, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (20.00) | 18.2507 |
| 2000's | 17 (37.78) | 29.6817 |
| 2010's | 17 (37.78) | 24.3611 |
| 2020's | 2 (4.44) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Ishida, H | 1 |
| Komaba, H | 1 |
| Hamano, N | 1 |
| Yamato, H | 1 |
| Sawada, K | 1 |
| Wada, T | 1 |
| Nakamura, M | 2 |
| Fukagawa, M | 1 |
| Ozaki, Y | 1 |
| Koide, M | 1 |
| Furuya, Y | 1 |
| Ninomiya, T | 1 |
| Yasuda, H | 1 |
| Kobayashi, Y | 1 |
| Takahashi, N | 1 |
| Yoshinari, N | 1 |
| Udagawa, N | 1 |
| Mukherjee, D | 1 |
| Srinivasan, B | 1 |
| Anbu, J | 1 |
| Azamthulla, M | 1 |
| Banala, VT | 1 |
| Ramachandra, SG | 1 |
| Randall, DR | 1 |
| Nativ-Zeltzer, N | 1 |
| Cates, DJ | 1 |
| Tinling, SP | 1 |
| Belafsky, PC | 1 |
| Doms, S | 1 |
| Verlinden, L | 1 |
| Vanhevel, J | 1 |
| Janssens, I | 1 |
| Bouillon, R | 1 |
| De Clercq, P | 1 |
| Verstuyf, A | 1 |
| Von Schacht, E | 1 |
| Dambacher, MA | 1 |
| Ringe, JD | 1 |
| Dukas, L | 1 |
| Thomsen, JS | 2 |
| Straarup, TS | 1 |
| Danielsen, CC | 2 |
| Oxlund, H | 1 |
| Brüel, A | 1 |
| Sahana, H | 1 |
| Khajuria, DK | 2 |
| Razdan, R | 2 |
| Mahapatra, DR | 2 |
| Bhat, MR | 1 |
| Suresh, S | 1 |
| Rao, RR | 1 |
| Mariappan, L | 1 |
| Kikuta, J | 1 |
| Ishii, M | 1 |
| Cankaya, D | 1 |
| Tabak, Y | 1 |
| Ozturk, AM | 1 |
| Gunay, MC | 1 |
| Permuy, M | 1 |
| Guede, D | 1 |
| López-Peña, M | 1 |
| Muñoz, F | 1 |
| Caeiro, JR | 1 |
| González-Cantalapiedra, A | 1 |
| Sugie-Oya, A | 1 |
| Takakura, A | 1 |
| Takao-Kawabata, R | 1 |
| Sano, H | 1 |
| Shimazu, Y | 1 |
| Isogai, Y | 1 |
| Yamaguchi, A | 1 |
| Ishizuya, T | 1 |
| Disha, C | 1 |
| Vasireddi, R | 1 |
| Rawat, P | 1 |
| Ahmad, I | 1 |
| Thomas, SC | 1 |
| Pandey, S | 1 |
| Vohora, D | 1 |
| Gupta, S | 1 |
| Ahmad, FJ | 1 |
| Talegaonkar, S | 1 |
| Iwamoto, J | 4 |
| Matsumoto, H | 1 |
| Takeda, T | 4 |
| Sato, Y | 4 |
| Liu, X | 1 |
| Yeh, JK | 4 |
| Lawson, MA | 1 |
| Coulton, L | 1 |
| Ebetino, FH | 1 |
| Vanderkerken, K | 1 |
| Croucher, PI | 1 |
| Brookler, K | 1 |
| Wang, X | 1 |
| Erickson, AM | 1 |
| Allen, MR | 1 |
| Burr, DB | 1 |
| Martin, RB | 1 |
| Hazelwood, SJ | 1 |
| Shiraishi, A | 1 |
| Miyabe, S | 1 |
| Nakano, T | 1 |
| Umakoshi, Y | 1 |
| Ito, M | 1 |
| Mihara, M | 1 |
| Jones, MD | 1 |
| Tran, CW | 1 |
| Li, G | 1 |
| Maksymowych, WP | 1 |
| Zernicke, RF | 2 |
| Doschak, MR | 2 |
| Heidari, P | 1 |
| Abbaspour, A | 1 |
| Baghdadi, T | 1 |
| Espandar, R | 1 |
| Farzan, M | 1 |
| Amanpour, S | 1 |
| Rasouli, MR | 1 |
| Mohagheghi, MA | 1 |
| Amiri, HR | 1 |
| Yasui, N | 1 |
| Orita, S | 1 |
| Ohtori, S | 1 |
| Koshi, T | 1 |
| Yamashita, M | 1 |
| Yamauchi, K | 1 |
| Inoue, G | 1 |
| Suzuki, M | 1 |
| Eguchi, Y | 1 |
| Kamoda, H | 1 |
| Arai, G | 1 |
| Ishikawa, T | 1 |
| Miyagi, M | 1 |
| Ochiai, N | 1 |
| Kishida, S | 1 |
| Takaso, M | 1 |
| Aoki, Y | 1 |
| Toyone, T | 1 |
| Takahashi, K | 1 |
| Geoffroy, V | 1 |
| Paschalis, EP | 1 |
| Libouban, H | 2 |
| Blouin, S | 1 |
| Ostertag, A | 1 |
| Chappard, D | 2 |
| Cros, M | 1 |
| Phipps, R | 1 |
| de Vernejoul, MC | 1 |
| Garzoni, LR | 1 |
| Waghabi, MC | 1 |
| Baptista, MM | 1 |
| de Castro, SL | 1 |
| Meirelles, Mde N | 1 |
| Britto, CC | 1 |
| Docampo, R | 1 |
| Oldfield, E | 1 |
| Urbina, JA | 1 |
| Shimshi, M | 1 |
| Abe, E | 1 |
| Fisher, EA | 1 |
| Zaidi, M | 1 |
| Fallon, JT | 1 |
| Bouzahzah, B | 1 |
| Jelicks, LA | 1 |
| Morris, SA | 1 |
| Weiss, LM | 1 |
| Tanowitz, HB | 1 |
| Wakchoure, S | 1 |
| Merrell, MA | 1 |
| Aldrich, W | 1 |
| Millender-Swain, T | 1 |
| Harris, KW | 1 |
| Triozzi, P | 1 |
| Selander, KS | 1 |
| Carvalho, AP | 1 |
| Bezerra, MM | 1 |
| Girão, VC | 1 |
| Cunha, FQ | 1 |
| Rocha, FA | 1 |
| Seki, A | 1 |
| Yamada, H | 1 |
| Shen, CL | 2 |
| Dalle Carbonare, L | 1 |
| Bertoldo, F | 1 |
| Valenti, MT | 1 |
| Zordan, S | 1 |
| Sella, S | 1 |
| Fassina, A | 1 |
| Turco, G | 1 |
| Realdi, G | 1 |
| Lo Cascio, V | 1 |
| Giannini, S | 1 |
| MacNeil, JA | 1 |
| Boyd, SK | 1 |
| Jee, WS | 3 |
| Lin, BY | 1 |
| Ma, YF | 2 |
| Ke, HZ | 2 |
| Li, M | 1 |
| Mosekilde, L | 2 |
| Søgaard, CH | 2 |
| Wronski, TJ | 6 |
| Boyce, RW | 1 |
| Ebert, DC | 1 |
| Stevens, ML | 1 |
| Paddock, CL | 1 |
| Youngs, TA | 1 |
| Gundersen, HJ | 1 |
| McOsker, JE | 2 |
| Baumann, BD | 1 |
| Dann, LM | 1 |
| Qi, H | 1 |
| Yen, CF | 1 |
| Liang, HH | 1 |
| Pan, Z | 1 |
| Setterberg, RB | 1 |
| Li, XJ | 2 |
| Ma, Y | 1 |
| Chen, Y | 1 |
| Gasser, J | 1 |
| Kimmel, DB | 1 |
| Li, QN | 1 |
| Liang, NC | 1 |
| Huang, LF | 1 |
| Wu, T | 1 |
| Hu, B | 1 |
| Mo, LE | 1 |
| Hunziker, J | 1 |
| Miller, SC | 1 |
| Moreau, MF | 1 |
| Legrand, E | 1 |
| Baslé, MF | 1 |
| Audran, M | 1 |
2 reviews available for risedronic acid and Disease Models, Animal
| Article | Year |
|---|---|
[Combination of alendronate plus alfacalcidol in the treatment of osteoporosis. Rationale, preclinical data and clinical evidence].
Topics: Aged; Alendronate; Animals; Bone Density; Disease Models, Animal; Drug Combinations; Drug Interactio | 2012 |
[Dynamics of bone resorption analyzed by intravital imaging].
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Resorption; Disease Models, Animal; | 2013 |
43 other studies available for risedronic acid and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Skeletal and mineral metabolic effects of risedronate in a rat model of high-turnover renal osteodystrophy.
Topics: Animals; Biomechanical Phenomena; Blood Urea Nitrogen; Bone and Bones; Bone Remodeling; Calcium; Chr | 2020 |
Treatment of OPG-deficient mice with WP9QY, a RANKL-binding peptide, recovers alveolar bone loss by suppressing osteoclastogenesis and enhancing osteoblastogenesis.
Topics: Adaptor Proteins, Signal Transducing; Alveolar Bone Loss; Animals; Bone Density Conservation Agents; | 2017 |
Improvement of bone microarchitecture in methylprednisolone induced rat model of osteoporosis by using thiolated chitosan-based risedronate mucoadhesive film.
Topics: Animals; Bone and Bones; Chitosan; Disease Models, Animal; Drug Compounding; Female; Methylprednisol | 2018 |
Decreased intramuscular calcium hydroxyapatite implant resorption in a murine model of osteoporosis.
Topics: Animals; Disease Models, Animal; Drug Implants; Durapatite; Female; Injections; Muscle, Skeletal; Os | 2018 |
WY 1048, a 17-methyl 19-nor D-ring analog of vitamin D
Topics: Animals; Bone Density; Bone Density Conservation Agents; Cholecalciferol; Disease Models, Animal; Fe | 2019 |
No effect of risedronate on articular cartilage damage in the Dunkin Hartley guinea pig model of osteoarthritis.
Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Calcification, Physiologic; Cartilage, A | 2013 |
Improvement in bone properties by using risedronate adsorbed hydroxyapatite novel nanoparticle based formulation in a rat model of osteoporosis.
Topics: Adsorption; Animals; Biomechanical Phenomena; Bone and Bones; Bone Density; Chemistry, Pharmaceutica | 2013 |
Perioperative alendronate, risedronate, calcitonin and indomethacin treatment alters femoral stem fixation and periprosthetic bone mineral density in ovariectomized rats.
Topics: Absorptiometry, Photon; Alendronate; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthroplasty, | 2015 |
Comparison of various SYSADOA for the osteoarthritis treatment: an experimental study in rabbits.
Topics: Animals; Anthraquinones; Anti-Inflammatory Agents; Arthrography; Bone Density Conservation Agents; C | 2015 |
Comparison of treatment effects of teriparatide and the bisphosphonate risedronate in an aged, osteopenic, ovariectomized rat model under various clinical conditions.
Topics: Aging; Animals; Bone Diseases, Metabolic; Disease Models, Animal; Female; Lumbar Vertebrae; Ovariect | 2016 |
Risedronate/zinc-hydroxyapatite based nanomedicine for osteoporosis.
Topics: Alkaline Phosphatase; Animals; Bone and Bones; Bone Density Conservation Agents; Calcium; Creatinine | 2016 |
Revisiting bone targeting potential of novel hydroxyapatite based surface modified PLGA nanoparticles of risedronate: Pharmacokinetic and biochemical assessment.
Topics: Animals; Biological Availability; Bone and Bones; Bone Density Conservation Agents; Cell Line; Cell | 2016 |
Effects of vitamin K(2) and risedronate on bone formation and resorption, osteocyte lacunar system, and porosity in the cortical bone of glucocorticoid-treated rats.
Topics: Animals; Body Weight; Bone Density Conservation Agents; Bone Resorption; Disease Models, Animal; Dru | 2008 |
Geranylgeranyl transferase type II inhibition prevents myeloma bone disease.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Cell Count; Diphosphonates; Disease Model | 2008 |
Medical treatment of otosclerosis: rationale for use of bisphosphonates.
Topics: Aged; Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Cell Death; Combined | 2008 |
Theoretical analysis of alendronate and risedronate effects on canine vertebral remodeling and microdamage.
Topics: Alendronate; Animals; Computer Simulation; Disease Models, Animal; Dogs; Etidronic Acid; Fractures, | 2009 |
The combination therapy with alfacalcidol and risedronate improves the mechanical property in lumbar spine by affecting the material properties in an ovariectomized rat model of osteoporosis.
Topics: Animals; Biomarkers; Biomechanical Phenomena; Bone Density; Bone Density Conservation Agents; Diseas | 2009 |
In vivo microfocal computed tomography and micro-magnetic resonance imaging evaluation of antiresorptive and antiinflammatory drugs as preventive treatments of osteoarthritis in the rat.
Topics: Alendronate; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bone Density Conservation Agents; Dis | 2010 |
Effect of risedronate on bone resorption during consolidation phase of distraction osteogenesis: a rabbit model.
Topics: Animals; Bone Density Conservation Agents; Bone Regeneration; Bone Resorption; Disease Models, Anima | 2010 |
The effects of risedronate and exercise on osteoporotic lumbar rat vertebrae and their sensory innervation.
Topics: Afferent Pathways; Animals; Back Pain; Bone Density Conservation Agents; Cells, Cultured; Disease Mo | 2010 |
Effects of risedronate in Runx2 overexpressing mice, an animal model for evaluation of treatment effects on bone quality and fractures.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Remodeling; Core Binding Factor Alph | 2011 |
Antiparasitic activity of risedronate in a murine model of acute Chagas' disease.
Topics: Acute Disease; Alkyl and Aryl Transferases; Animals; Chagas Disease; Disease Models, Animal; Enzyme | 2004 |
Bisphosphonates induce inflammation and rupture of atherosclerotic plaques in apolipoprotein-E null mice.
Topics: Alendronate; Animals; Aorta; Apolipoproteins E; Arteriosclerosis; Carotid Stenosis; Diphosphonates; | 2005 |
Risedronate in the treatment of Murine Chagas' disease.
Topics: Animals; Chagas Cardiomyopathy; Chagas Disease; Disease Models, Animal; Etidronic Acid; Mice; Mice, | 2005 |
Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo.
Topics: Animals; Cell Division; Cell Line, Tumor; Diphosphonates; Disease Models, Animal; Etidronic Acid; Im | 2006 |
Anti-inflammatory and anti-nociceptive activity of risedronate in experimental pain models in rats and mice.
Topics: Acetic Acid; Analgesics; Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Diphosphonates; | 2006 |
Therapeutic effect of risedronate on cancellous and cortical bone in ovariectomized osteopenic rats: a comparison with the effects of alfacalcidol.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Diseases, Metabolic; Disease Models, | 2006 |
Effect of pre- and post-surgery treatment with risedronate on trabecular bone loss in ovariectomized rats.
Topics: Absorptiometry, Photon; Animals; Bone Density; Bone Density Conservation Agents; Bone Diseases, Meta | 2006 |
Beneficial effect of pretreatment and treatment continuation with risedronate and vitamin K2 on cancellous bone loss after ovariectomy in rats: a bone histomorphometry study.
Topics: Absorptiometry, Photon; Analysis of Variance; Animals; Body Weight; Bone Density; Bone Density Conse | 2006 |
Risedronate prevents the loss of microarchitecture in glucocorticoid-induced osteoporosis in rats.
Topics: Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Resorption; Disease Mo | 2007 |
Preservation of periarticular cancellous morphology and mechanical stiffness in post-traumatic experimental osteoarthritis by antiresorptive therapy.
Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Computer Simulation; Disease Models, Ani | 2008 |
Extra cancellous bone induced by combined prostaglandin E2 and risedronate administration is maintained after their withdrawal in older female rats.
Topics: Aging; Analysis of Variance; Animals; Body Weight; Bone Development; Bone Resorption; Calcium Channe | 1995 |
Parathyroid hormone monotherapy and cotherapy with antiresorptive agents restore vertebral bone mass and strength in aged ovariectomized rats.
Topics: Animals; Biomechanical Phenomena; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Calcitoni | 1995 |
Direct stereological estimation of three-dimensional connectivity in rat vertebrae: effect of estrogen, etidronate and risedronate following ovariectomy.
Topics: Animals; Bone Resorption; Calcium Channel Blockers; Disease Models, Animal; Estradiol; Etidronic Aci | 1995 |
The anabolic effects of parathyroid hormone on cortical bone mass, dimensions and strength--assessed in a sexually mature, ovariectomized rat model.
Topics: Analysis of Variance; Animals; Biomechanical Phenomena; Bone Density; Bone Diseases, Metabolic; Bone | 1995 |
Response of cortical bone to antiresorptive agents and parathyroid hormone in aged ovariectomized rats.
Topics: Animals; Biomarkers; Bone Density; Bone Development; Bone Resorption; Calcitonin; Disease Models, An | 1995 |
Skeletal effects of withdrawal of estrogen and diphosphonate treatment in ovariectomized rats.
Topics: Animals; Bone and Bones; Bone Diseases, Metabolic; Disease Models, Animal; Estradiol; Etidronic Acid | 1993 |
Risedronate plus prostaglandin E2 is superior to prostaglandin E2 alone in maintaining the added bone after withdrawal in a non-growing bone site in ovariectomized rats.
Topics: Analysis of Variance; Animals; Bone Diseases, Metabolic; Dinoprostone; Disease Models, Animal; Drug | 1995 |
Partial maintenance of extra cancellous bone mass by antiresorptive agents after discontinuation of human parathyroid hormone (1-38) in right hindlimb immobilized rats.
Topics: Animals; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Calcitonin; Disease Models, Animal | 1995 |
Skeletal effects of constant and terminated use of risedronate on cortical bone in ovariectomized rats.
Topics: Animals; Bone and Bones; Bone Remodeling; Disease Models, Animal; Drug Administration Schedule; Etid | 1999 |
Mandibular bone formation rates in aged ovariectomized rats treated with anti-resorptive agents alone and in combination with intermittent parathyroid hormone.
Topics: Analysis of Variance; Animals; Bone Resorption; Calcitonin; Calcium Channel Blockers; Diphosphonates | 2000 |
Comparison insight dual X-ray absorptiometry (DXA), histomorphometry, ash weight, and morphometric indices for bone evaluation in an animal model (the orchidectomized rat) of male osteoporosis.
Topics: Absorptiometry, Photon; Animals; Body Weight; Bone and Bones; Bone Density; Climacteric; Disease Mod | 2001 |